|Committee Member||Employment||Consultant||Speakers Bureau||Ownership/Partnership/Principal||Personal Research||Institutional/Organizational or Other Financial Benefit||Expert Witness|
|John R. Windle (Chair)||University of Nebraska Medical Center—Professor and Chief, Internal Medicine|
Division of Cardiology
|Alan S. Katz (Vice Chair)||Catholic Health Services—Vice President, Medical Informatics||None||None||None||None||None|
|J. Paul Dow Jr.||American College of Cardiology—Healthcare Technology Associate||None||None||None||None||None||None|
|Edward T.A. Fry||St. Vincent Medical Group—Interventional Cardiologist||None||None||None||None||None||None|
|Andrew M. Keller||Danbury Hospital—Chief of Cardiology||None||None||None||None||None||None|
|Terran Lamp||Shionogi, Inc.—Pharmaceutical Sales Consultant||None||None||None||None||None||None|
|Alexander Lippitt, Jr.||Health Information Management and Systems Society—Senior Director, Interoperability and Standards (former employment during writing effort)||None||None||None||None||None||None|
|Marianne P. Paruche||NYU Langone Medical Center, EP Lab—Administrative Director||None||None||None||None||None||None|
|Frederic S. Resnic||Lahey Clinic Medical Center—Chairman, Department of Cardiovascular Medicine||None||None||None||None||None|
|Gerald A. Serwer||University of Michigan Congenital Heart Center, University of Michigan Health Systems—Professor of Pediatric Cardiology||None||None||None||None||None|
|David J. Slotwiner||Weill Cornell Medical College—Assistant Professor of Medicine||None||None||None||None||None||None|
|James E. Tcheng||Duke University Medical Center—Professor of Medicine||None||None||None||None||None|
|Peter L. Tilkemeier||Greenville Health System—Chairman of Internal Medicine||None||None||None||None||None||None|
|Bonnie H. Weiner||St. Vincent Hospital—Training Director||None||None||None||None|
|William S. Weintraub||Christiana Care Health System—Section Chief, Cardiology||None||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
↵∗ No financial benefit.